A Review of the Existing Grading Schemes and a Proposal for a Modified Grading Scheme for Prostatic Lesions in TRAMP Mice
暂无分享,去创建一个
S. Kulp | C. Chen | T. Rosol | S. Clinton | A. Sargeant | L. Berman-Booty | Robert C. Rengel | Ching S. Chen
[1] S. Kulp,et al. OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model. , 2008, Cancer research.
[2] R. Cardiff,et al. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. , 2008, The American journal of pathology.
[3] S. Kulp,et al. Chemopreventive and Bioenergetic Signaling Effects of PDK1/Akt Pathway Inhibition in a Transgenic Mouse Model of Prostate Cancer , 2007, Toxicologic pathology.
[4] O. Ogawa,et al. Epithelial stromal tumor of the seminal vesicle , 2006, International journal of urology : official journal of the Japanese Urological Association.
[5] T. Ratliff. Prostate Pathology of Genetically Engineered Mice: Definitions and Classification. The Consensus Report From the Bar Harbor Meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee , 2004 .
[6] M. Rubin,et al. Prostate Pathology of Genetically Engineered Mice: Definitions and Classification. The Consensus Report from the Bar Harbor Meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee , 2004, Cancer Research.
[7] Tsuey-Ming Chen,et al. Pathobiology of autochthonous prostate cancer in a pre‐clinical transgenic mouse model , 2003, The Prostate.
[8] J. Haseman,et al. A Grading Scheme for the Assessment of Proliferative Lesions of the Mouse Prostate in the TRAMP Model , 2003, Toxicologic pathology.
[9] B. Foster,et al. The TRAMP Mouse as a Model for Prostate Cancer , 2001, Current protocols in immunology.
[10] H. Bonkhoff. Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] N. Greenberg,et al. E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. , 2000, Cancer research.
[12] B. Foster,et al. Pathologic progression of autochthonous prostate cancer in the TRAMP model , 1999, Prostate Cancer and Prostatic Diseases.
[13] M. Kattan,et al. Androgen-independent prostate cancer progression in the TRAMP model. , 1997, Cancer research.
[14] J. Rosen,et al. Metastatic prostate cancer in a transgenic mouse. , 1996, Cancer research.
[15] N. Greenberg. Transgenic models for prostate cancer research. , 1996, Urologic oncology.
[16] R. Matusik,et al. Prostate cancer in a transgenic mouse. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[17] R. Matusik,et al. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. , 1994, Molecular endocrinology.